Study compares switching meds vs. an additional med for patients unresponsive to an antidepressant

July 11, 2017

Among patients unresponsive to an antidepressant medication, adding the antipsychotic aripiprazole modestly increased the likelihood of remission from depression compared to switching to the antidepressant bupropion, according to a study published by JAMA.

Major depressive disorder (MDD) is a chronic, debilitating disorder that affected an estimated 16 million adults in the United States in 2015. Less than one-third of patients achieve remission with their first antidepressant. Somaia Mohamed, M.D., Ph.D., of the VA Connecticut Healthcare System, West Haven, Conn., and colleagues randomly assigned 1,522 patients at 35 U.S. Veterans Health Administration medical centers diagnosed with MDD and unresponsive to at least one antidepressant to switch to a different antidepressant (bupropion; n = 511); augment current treatment with bupropion (n = 506); or augment with aripiprazole (n = 505) for 12 weeks (treatment phase) and evaluated for up to 36 weeks.

Among the patients (average age, 54 years; men, 85 percent), 75 percent completed the treatment phase. Depression remission rates at 12 weeks were 22.3 percent for the switch group, 26.9 percent for the augment-bupropion group, and 28.9 percent for the augment¬ aripiprazole group. Symptom improvement was greater for the augment-aripiprazole group than for either the switch group or the augment-bupropion group.

Anxiety was more frequent in the two bupropion groups.

Adverse effects more frequent in the augment-aripiprazole group included drowsiness, restlessness and weight gain. "Given the small effect size and adverse effects associated with aripiprazole, further analysis including cost-effectiveness is needed to understand the net utility of this approach," the authors write.

A limitation of the study was that only one antidepressant and one antipsychotic were evaluated, and the generalizability of the results to other medications is unknown.
-end-
For more details and to read the full study, please visit the For The Media website.

(doi:10.1001/jama.2017.8036)

Editor's Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

Related material: The editorial, "Lessons Learned From the VA Augmentation and Switching Treatments for Improving Depression Outcomes Study," by Maurizio Fava, M.D., of Massachusetts General Hospital, Boston, also is available at the For The Media website.

To place an electronic embedded link to this study in your story This link will be live at the embargo time: http://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2017.8036

The JAMA Network Journals

Related Antidepressant Articles from Brightsurf:

Antidepressant may prevent severe COVID-19, trial suggests
The antidepressant fluvoxamine appears to prevent COVID-19 infections from worsening and may help keep patients out of the hospital, a trial based on research from the University of Virginia School of Medicine suggests.

Trajectories of antidepressant medication use during pregnancy
In an analysis of women who started pregnancy when taking antidepressant medications, investigators identified three trajectories of antidepressant dispensing during pregnancy: more than half stopped their treatment, a quarter maintained their treatment throughout pregnancy, and one-fifth discontinued it for a minimum of three months and then resumed it during the postpartum period.

Decades-old antidepressant may fend off prostate cancer's return
An antidepressant from the '50s, repurposed to fight prostate cancer, lowered PSA levels in men with recurrent disease, pilot study shows.

Researchers say extended antidepressant use creates physical dependence
Researchers explain symptoms associated with Antidepressant Discontinuation Syndrome and provide a schedule for tapering various classes of antidepressants.

Number of depressed over-65s unchanged but antidepressant use soars
The proportion of people aged over 65 on antidepressants has more than doubled in two decades -- according to new research led by the University of East Anglia.

Antidepressant medications appear to be generally safe
Antidepressants are generally safe, according to a new study by an international team of researchers.

Why is ketamine an antidepressant?
Delving deep inside the neural circuitry of 'depressed' mice, researchers have revealed how ketamine works in cells to achieve its fast-acting antidepressant effect.

Childhood methylphenidate treatment predicts antidepressant use during adolescence
A new, 12-year longitudinal study, which monitored 6,830 children from early childhood into adolescence, has shown that consistent treatment with MPH-based medications during childhood increases the risk of antidepressant use during adolescence.

Antidepressant could stop deadly sepsis, study suggests
An antidepressant drug used to treat obsessive-compulsive disorder could save people from deadly sepsis, new research suggests.

Overprescribing of antidepressant medications may be common in elderly patients
In a Pharmacology Research & Perspectives study of individuals living in Olmsted County, Minnesota from 2005-2012, potential overprescribing of antidepressant medications occurred in nearly one-quarter of elderly residents.

Read More: Antidepressant News and Antidepressant Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.